
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Supplements and Featured Publications
Coverage of the 2023 American Thoracic Society International Conference, which took place in Washington, DC.






